- Home
- EXEL vs HOLX Comparison
EXEL vs HOLX Comparison
Compare EXEL & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- HOLX
- Stock Information
- Founded
- EXEL 1994
- HOLX 1985
- Country
- EXEL United States
- HOLX United States
- Employees
- EXEL 1147
- HOLX N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- HOLX Medical Electronics
- Sector
- EXEL Health Care
- HOLX Health Care
- Exchange
- EXEL Nasdaq
- HOLX Nasdaq
- Market Cap
- EXEL 11.3B
- HOLX 12.1B
- IPO Year
- EXEL 2000
- HOLX 1990
- Fundamental
- Price
- EXEL $40.37
- HOLX $64.48
- Analyst Decision
- EXEL Buy
- HOLX Hold
- Analyst Count
- EXEL 18
- HOLX 13
- Target Price
- EXEL $39.59
- HOLX $76.27
- AVG Volume (30 Days)
- EXEL 2.6M
- HOLX 3.8M
- Earning Date
- EXEL 08-05-2025
- HOLX 07-28-2025
- Dividend Yield
- EXEL N/A
- HOLX N/A
- EPS Growth
- EXEL 237.58
- HOLX 25.36
- EPS
- EXEL 2.20
- HOLX 2.39
- Revenue
- EXEL $2,298,922,000.00
- HOLX $4,026,500,000.00
- Revenue This Year
- EXEL $9.37
- HOLX $2.99
- Revenue Next Year
- EXEL $11.05
- HOLX $4.91
- P/E Ratio
- EXEL $18.12
- HOLX $26.76
- Revenue Growth
- EXEL 24.49
- HOLX 1.66
- 52 Week Low
- EXEL $21.36
- HOLX $51.90
- 52 Week High
- EXEL $48.85
- HOLX $84.67
- Technical
- Relative Strength Index (RSI)
- EXEL 42.39
- HOLX 60.95
- Support Level
- EXEL $41.03
- HOLX $63.76
- Resistance Level
- EXEL $42.07
- HOLX $65.72
- Average True Range (ATR)
- EXEL 0.95
- HOLX 1.35
- MACD
- EXEL -0.42
- HOLX -0.03
- Stochastic Oscillator
- EXEL 12.85
- HOLX 72.07
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.